ArticleCureus2026
Right Frontal Isocitrate Dehydrogenase (IDH)-Mutant WHO Grade 3 Oligodendroglioma Presenting With Morning Headache and Gait Imbalance.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oligodendroglioma is a diffuse glioma characterized by isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion. We report the case of a 45-year-old woman who presented with progressive headaches, nausea, vomiting, blurred vision, and gait imbalance associated with rapid neurological deterioration. Neuroimaging demonstrated a large right frontal intra-axial lesion with heterogeneous enhancement, cystic components, surrounding edema, and significant mass effect with midline shift. The patient underwent subtotal surgical resection, and histopathological evaluation confirmed an IDH-mutant, 1p/19q-codeleted oligodendroglioma. Postoperatively, she received adjuvant chemoradiotherapy followed by temozolomide, with subsequent clinical and radiographic improvement. This case highlights the importance of early recognition of progressive neurological symptoms and multidisciplinary management in patients presenting with aggressive intracranial tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.